The latest update puts LTM’s fair value at ₹5,951.97, compared with the prior ₹6,219.67. This comes alongside an analyst price target that has shifted from US$53 to US$58 after the recent selloff.
Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced its abstract has been ...